The use of mammalian target of rapamycin (mTOR) inhibitors after liver transplantation has been associated with favourable benefits on renal function but with efficacy comparable to CNIs and therefore would be a good alternative in IBD patients following LTx [55]. This evidence concerns the gene MTOR and inflammatory bowel disease.